Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.

Ghusn W, Fansa S, Anazco D, Tama E, Nicolalde B, Gala K, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feres F, Hurtado MD, Acosta A

International journal of obesity (2005)1 Feb 2024Cited by 21 (Europe PMC)

PMID38302591DOI10.1038/s41366-023-01456-5PepBankPUB-38302591

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In adults with overweight or obesity, subcutaneous semaglutide gave a total body weight loss of 13.4% at 12 months.
In plain wordsIn adults with overweight or obesity, semaglutide led to an average body weight loss of 13.4% after 12 months.
Peptide
Semaglutide
Outcome
DecreaseTotal body weight loss at 12 months
Study
n = 304
Comparator
Baseline
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
TBWL
13.4%
12 months
Source sentences
Summary
Patients achieved a TBWL of 13.4 (8.0)% at 12 months (p < 0.001 from baseline).
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259101
02HumanObservational studyEfficacy outcome
In adults with overweight or obesity, 81% achieved at least 5% total body weight loss at 12 months with semaglutide.
In plain wordsIn adults with overweight or obesity, 81% lost at least 5% of body weight after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion achieving 5% or more weight loss
Study
n = 304
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Proportion with TBWL >=5%
81%
12 months
Source sentences
Summary
81% achieved ≥5%
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259104
03HumanObservational studyEfficacy outcome
In adults with overweight or obesity, 64% achieved at least 10% total body weight loss at 12 months with semaglutide.
In plain wordsIn adults with overweight or obesity, 64% lost at least 10% of body weight after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion achieving 10% or more weight loss
Study
n = 304
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Proportion with TBWL >=10%
64%
12 months
Source sentences
Summary
64% achieved ≥10%
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259105
04HumanObservational studyEfficacy outcome
In adults with overweight or obesity, 41% achieved at least 15% total body weight loss at 12 months with semaglutide.
In plain wordsIn adults with overweight or obesity, 41% lost at least 15% of body weight after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion achieving 15% or more weight loss
Study
n = 304
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Proportion with TBWL >=15%
41%
12 months
Source sentences
Summary
41% achieved ≥15%
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259106
05HumanObservational studyEfficacy outcome
In adults with overweight or obesity, 22% achieved at least 20% total body weight loss at 12 months with semaglutide.
In plain wordsIn adults with overweight or obesity, 22% lost at least 20% of body weight after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion achieving 20% or more weight loss
Study
n = 304
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Proportion with TBWL >=20%
22%
12 months
Source sentences
Summary
22% achieved ≥20% TBWL at 12 months
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259107
06HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide was followed by significant improvements in metabolic outcomes at 12 months.
In plain wordsIn adults with overweight or obesity, metabolic measures improved during 12 months of semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedMetabolic outcomes at 12 months
Study
n = 304
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259108
07HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide was followed by significant improvements in the lipid profile at 12 months.
In plain wordsIn adults with overweight or obesity, blood fat measures improved during 12 months of semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedLipid profile at 12 months
Study
n = 304
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259109
08HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide was followed by significant improvements in blood pressure at 12 months.
In plain wordsIn adults with overweight or obesity, blood pressure improved during 12 months of semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedBlood pressure at 12 months
Study
n = 304
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259110
09HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide was followed by significant improvements in liver function tests at 12 months.
In plain wordsIn adults with overweight or obesity, liver test results improved during 12 months of semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedLiver function tests at 12 months
Study
n = 304
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259111
10HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide was followed by significant improvements in cardiovascular disease risk outcomes at 12 months.
In plain wordsIn adults with overweight or obesity, heart disease risk measures improved during 12 months of semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedCardiovascular disease risk outcomes at 12 months
Study
n = 304
Comparator
Baseline
Outcome group
Cardiometabolic risk factors · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Patients with overweight or obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and cardiovascular disease risk outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259112
11HumanObservational studyEfficacy outcome
In patients without type 2 diabetes, semaglutide gave a total body weight loss of 16.9% at 12 months on the higher doses.
In plain wordsIn people without type 2 diabetes, semaglutide led to an average weight loss of 16.9% after 12 months.
Peptide
Semaglutide
Outcome
DecreaseTotal body weight loss at 12 months, first subgroup (labelled without T2DM)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
TBWL
16.9%
without T2DM, 12 months
Source sentences
Summary
Patients without T2DM achieved a TBWL of 16.9 (6.9)%
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259102
12HumanObservational studyEfficacy outcome
In the comparison subgroup, which the abstract also labels as patients without T2DM, semaglutide gave a total body weight loss of 9.9% at 12 months on the higher doses.
In plain wordsIn the second subgroup, semaglutide led to an average weight loss of 9.9% after 12 months.
Peptide
Semaglutide
Outcome
DecreaseTotal body weight loss at 12 months, second subgroup (labelled without T2DM, probably with T2DM)
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
TBWL
9.9%
second subgroup, 12 months
Source sentences
Summary
Patients without T2DM achieved a TBWL of 16.9 (6.9)% compared to 9.9 (8.4)% in patients without T2DM at 12 months on the higher doses of semaglutide (p < 0.001 from baseline).
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a multicentered retrospective cohort study on semaglutide use.
Summary · context
We included patients with a body-mass index (BMI) ≥ 27 kg/m² who were prescribed weekly semaglutide subcutaneous injections.
Summary · context
We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²) in the analysis.
Report a problemFND-3830259103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.